A Phase 4 interventional study of Lacidofil and Placebo in Pneumonia, Probiotics and Diarrhea, sponsored by National Health Insurance Service Ilsan Hospital. Not yet recruiting. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by National Health Insurance Service Ilsan Hospital · Phase 4, Interventional, and Prevention
The study goal is to determine whether oral administration of a probiotic mixture can reduce the incidence of antibiotic-associated diarrhea in patients with community-acquired pneumonia.
1,564 studies on the registry are indexed under Pneumonia; 265 are open to participants now.
This study's planned enrollment of 100 is below the median of 129 across 975 interventional studies indexed under Pneumonia.
Browse Pneumonia studies →National Health Insurance Service Ilsan Hospital is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Take 1 capsule of Lacidofil in the morning and evening after meals, for a total of 2 times a day. The total duration of the dosage is the antibiotic treatment period plus 5 days.
Drug: Lacidofil
Take 1 capsule of placebo in the morning and evening after meals, for a total of 2 times a day. The total duration of the dosage is the antibiotic treatment period plus 5 days.
Drug: Placebo
1 capsule twice daily.
1 capsule twice daily.
Occurrence of antibiotic-associated diarrhea
Antibiotic-Associated Diarrhea (Definition: Occurrence of diarrhea more than 3 times a day, occurring at least 24 hours after the first administration of antibiotics) \* Diarrhea is defined using the Bristol Stool Form Scale (BSF) as BSF 6 or 7. BSF 6: Mushy stool \[Soft pieces with ragged edges, mushy stool\] BSF 7: Watery stool \[Liquid-like, no solid form, completely liquid\]
Time frame: Within 14 days after the cessation of Lacidofil or placebo administration
Occurrence of Clostridium difficile infection
Positive result in Clostridium difficile test: toxin, X-pert, or culture
Time frame: Within 14 days after the cessation of Lacidofil or placebo administration
Total length of hospitalization
the duration from admission to discharge
Time frame: Within 14 days after the cessation of Lacidofil or placebo administration
Duration of antibiotic use
period of antibiotic use during hospitalization + duration of oral antibiotic use after discharge
Time frame: Within 14 days after the cessation of Lacidofil or placebo administration
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Health Insurance Service Ilsan Hospital